Back

SGLT2i is indicated for all HFpEF patients - pro.

23 May 2022 (08:30 - 08:50)
Organised by:
Congress Presentation Part of: SGLT2i for HFpEF Chronic Heart Failure HFA Premium Access Heart Failure 2022

About the speaker

Photo
Professor Andrew Stewart Coats

Heart Research Institute, Sydney (Australia)

2 More presentations in this session

Presentation thumbnail
SGLT2i is indicated for all HFpEF patients - con.
Professor S. Harikrishnan (Thiruvananthapuram, IN)
Slides Video
Presentation thumbnail
SGLT2i for HFpEF - rebuttal and discussion.
Video

Access the full session

Session thumbnail
SGLT2i for HFpEF
Video

The Event

Event poster

Heart Failure 2022

23 May 2022 08:30 CET
You may be interested in
thumbnail
Congress Presentation
SGLT2 inhibitors: evidence across the spectrum of heart failure.
26 August 2022
thumbnail
Congress Session
SGLT-2 inhibitors - Another piece of the puzzle in heart failure
29 August 2022
thumbnail
Congress Presentation
Broadening the scope: should we implement guideline-directed medical therapy across all left ventricular ejection fraction ranges?
18 May 2025
thumbnail
Congress Presentation
SGLT2 inhibitors in HFmrEF and HFpEF: fulfilling an unmet need?
21 May 2022

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources